Dr. MONIKA LAMBA SAINI joins Dr. Mark Gramling for a broader discussion beyond the usual trial-focused topics in this episode. This time, they explore the world of pathology and the latest technological advancements.

Key points include:

• The clinical applications of technology in pathology, where Dr. Monika shares insights from her experience in both molecular and digital pathology.
• How AI is playing a role in diagnostic applications and how pathologists work and improve patient outcomes.

Dr. Monika Lamba Saini, MBBS, MD, Ph.D., is the ‘Global Translational Pathology leader’ at ADC Therapeutics, where she is responsible for the scientific strategy, including the development and implementation of translational tissue-based biomarkers and using digital pathology as a tool to expedite the development pipeline. She previously served as the Director of Digital Pathology Innovation at Q2 Solutions, IQVIA, Edinburgh, where she provided stewardship of digital pathology from validation to implementation of the digital pathology systems, as well as providing pathology support for AI-based algorithms and digital image analyses. She is a pathologist-scientist with 20+ years of experience and proficiency in pathology. She comes with extensive experience in oncopathology, molecular pathology, and digital pathology with her PhD at the Université catholique de Louvain, Brussels, Belgium. She has been the principal investigator and sub-investigator of clinical trials for companion diagnostics in oncology with Cell Carta Belgium. Her experience spans across different countries and continents. She is the author and reviewer of many publications, including Lancet and Nature, and an invited speaker on international platforms. Professional interests include translational research, cancer biology, immunopathology, digital pathology, project design and management, medical writing/publications and public speaking.

Tune in to hear how these developments are shaping the future of pathology and clinical diagnostics.

In this episode of the LARVOL Onco Data Podcast, Bruno Larvol and Dr. Mark Gramling dive into key findings from ASTRO 2024. They explore some of the top insights presented at the conference, analyzing their impact and the reaction across social media and within the oncology community. Listeners will also learn how LARVOL CLIN offers insights through data analytics and social media response tracking for conferences like ASTRO. If you're involved in oncology research or pharma, this episode is packed with ways to make the most of conference data and highlights how you can explore these tools for your next event.

In this engaging episode of the LARVOL Onco Data Podcast, Guru Sonpavde, MD, and Dr. Amol Akhade delve into key takeaways from the latest oncology discussions at ESMO24. The conversation highlights the expanding treatment options for physicians. Our VP of Oncology, Dr. Mark Gramling, emphasized the importance of focusing on the optimal sequencing of treatments like Ambassador, Niagara, EV-302, and Litespark. While more study is needed to determine the best approach, having these additional options is a win for patient care. Dr. Guru shares his thoughts on these important trials and how they have shaped recent discussions in GU cancer research. Dr. Amol adds his perspective on the significance of these trials and the need for continued research. As the episode wraps up, both experts emphasize the value of ongoing collaboration and research, promising more in-depth discussions in the future. Don’t miss out on this lively exchange of insights into the latest advancements in urologic oncology! Check out clin.larvol.com for more oncology data, and don’t forget to follow Dr. Guru and Dr. Amol on social media for updates on future trials. #ESMO24 #GUOncology #AmbassadorTrial #NiagaraTrial #EV302 #Litespark #Oncology #LARVOL

Post-ESMO - European Society for Medical Oncology Insights with Christian Hayden from Opus Strategy, LLC and Mark Gramling In this episode of the LARVOL Onco Data Podcast, Mark Gramling teams up with Christian Hayden from Opus Strategy to deliver rapid-fire insights following the ESMO conference. They dive into the outcomes of the Tevosa trial, discussing how, despite some disappointing results, the trial addressed critical research questions that will guide future oncological treatments. Christian and Mark also explore the role of clinical research in shaping oncology care and how findings like these influence oncologists’ decisions worldwide. The conversation balances analysis with a lighthearted wrap-up, reflecting on the importance of transparency in clinical trials. Tune in for takeaways from ESMO and beyond, and catch up on how Opus Strategy and LARVOL are navigating the evolving oncology landscape!

#ONCOLOGY #LARVOL #ESMO

🎙️ LARVOL Onco Data Podcast with Dr. Kevin Punie In this episode of the LARVOL Onco Data Podcast, Dr. Kevin Punie joins host Dr. Mark Gramling to discuss the latest insights from ESMO, focusing on key abstracts and social media reactions from the oncology community. Together, they explore critical updates in oncology, including a deep dive into triple-negative breast cancer and how new data is shaping clinical practices. Tune in for an engaging conversation that highlights the role of social media in driving oncology discourse and the future of cancer treatment. For more conference insights and data, visit clint.larvol.com and access real-time updates. #LARVOLPodcast #Oncology #ESMO2024 #CancerResearch #Oncology

Join us for an episode of the LARVOL Onco Data Podcast where Mark Gramling, VP of Oncology at LARVOL, hosts Christian Hayden from Opus Strategy for a Post-World Lung Cancer Conference (WCLC) analysis. Mark and Christian dive into key discussions surrounding emerging oncology targets and reflect on the recent Tropion trial’s ups and downs. They provide valuable insights into the latest data, exploring the landscape of new targets and therapies in different markets and geographies. 💡 Key Topics Discussed: • Reflections on the Tropion trial and its implications in oncology • Analyzing new targets and their impact across various geographies Don’t miss this conversation about the nuances of oncology data and strategy. For more on strategic consulting in the pharma space, reach out to Christian Hayden at Opus Strategy. For oncology data support, LARVOL is here to assist. #Oncology #LARVOL #WCLC #ClinicalTrials

Join Dr. Wafik S. El-Deiry, and Dr. Mark Gramling as they discuss the potential of immune response in future cancer treatments and the challenge of managing rapidly evolving oncology data. They explore how clinicians navigate new genetic insights and the continuous progress in cancer research.

🔍 Highlights: • Future potential of immune-based cancer cures • Navigating the ever-growing landscape of oncology data Listen in for insights on the evolving challenges and opportunities in oncology. #Oncology #CancerResearch #LARVOL

LARVOL ONCO DATA Podcast: AI and Outcomes Predictions with Mark Gramling In this solo episode, Mark Gramling dives into the role of AI in predicting outcomes within oncology. Mark discusses how AI technologies are being leveraged to forecast clinical outcomes and improve patient care. Additionally, he highlights upcoming events where these advancements will be showcased. 🔍 What to Expect: • Insights into the latest AI advancements and their practical applications in clinical practice • An overview of upcoming events where these AI-driven innovations will be featured Join us to explore what to look forward to in the upcoming events.